# Add-on Intravenous Immunoglobulins in Early Myositis

> **NCT05832034** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)** · enrollment: 44 (actual)

## Conditions studied

- Inflammatory Myopathy, Idiopathic
- Dermatomyositis
- Antisynthetase Syndrome
- Immune-Mediated Necrotizing Myopathy
- Polymyositis
- Myositis

## Interventions

- **DRUG:** Immune Globulin Intravenous (Human)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05832034
- **Lead sponsor:** Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-13
- **Primary completion:** 2025-09-25
- **Final completion:** 2026-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05832034

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05832034, "Add-on Intravenous Immunoglobulins in Early Myositis". Retrieved via AI Analytics 2026-07-31 from https://api.ai-analytics.org/clinical/NCT05832034. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*